Bio-Path Holdings to Announce Third Quarter 2021 Financial Results on November 12, 2021

Rhea-AI Summary

Bio-Path Holdings (NASDAQ: BPTH) will hold a conference call on November 12, 2021, at 8:30 a.m. ET to discuss its third-quarter financial results for the period ending September 30, 2021. The company is focused on developing its proprietary DNAbilize^® antisense RNAi nanoparticle technology to treat cancers. Bio-Path's lead candidate, prexigebersen (BP1001), is in a Phase 2 trial targeting blood cancers. It is also developing BP1002 and BP1003, with an IND filing expected in 2022 for BP1003. Access to the call can be made via phone or through a live webcast on the company’s website.

Positive

• The upcoming conference call on November 12, 2021, will provide financial results and business updates.
• Bio-Path's lead candidate, prexigebersen (BP1001), is currently in a Phase 2 study, indicating progress in clinical trials.
• The company has plans for additional product candidates, enhancing its pipeline.

Negative

• None.

HOUSTON, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize^® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, November 12, 2021 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2021 and to provide a business overview.

To access the live conference call, please call (844) 815-4963 (domestic) or (210) 229-8838 (international) at least five minutes prior to the start time and refer to conference ID 6684508. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event.

About Bio-Path Holdings, Inc.

Bio-Path is a biotechnology company developing DNAbilize^®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for the treatment of blood cancers. The Company’s second product BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. In addition, an IND is expected to be filed for BP1003, a novel liposome incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3, in 2022. The Company’s fourth product, prexigebersen-A, or BP1001-A, has been cleared to initiate a Phase 1/1b clinical trial of prexigebersen-A in patients with solid tumors, including ovarian, endometrial, pancreatic and triple negative breast cancer.

For more information, please visit the Company's website at http://www.biopathholdings.com.

Contact Information:
                        
Investors

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com  

Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369

FAQ

When will Bio-Path Holdings report its third-quarter financial results?

Bio-Path Holdings will report its third-quarter financial results on November 12, 2021.

What is the focus of Bio-Path Holdings' development efforts?

Bio-Path Holdings is focused on developing targeted nucleic acid cancer drugs using its DNAbilize^® technology.

Which clinical trials are currently ongoing for Bio-Path's products?

Bio-Path is conducting a Phase 2 study for its lead product candidate, prexigebersen (BP1001), targeting blood cancers.

How can I access the conference call for Bio-Path Holdings?

To access the conference call, dial (844) 815-4963 domestically or (210) 229-8838 internationally, or visit the company’s website for the live audio webcast.